Despite the anticipated sharp drop in sales from its generic version of Revlimid in 2026, analysts at Piper Sandler have emphasized Duvakitug’s potential to support Teva’s expansion.

Teva's long-term upside is also supported by pipeline catalysts. Duvakitug, a promising anti-TL1A immunology asset developed with Sanofi, has shown best-in-class Phase 2b data and could emerge as ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we ...

EPYSQLI is designed to treat gMG in adults who are anti-acetylcholine receptor antibody positive.

Teva Pharmaceutical Industries (NYSE:TEVA) recently received FDA acceptance of its supplemental Biologics License Application to expand AJOVY®'s use for preventing migraines in pediatric patients ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...